Moreover, PARP inhibitors have been proved to have therapeutic potential for tumors with DDR defects (including ATM and ATR mutations) [206, 207], and might also be used to treat advanced AM in the future. This evidence concerns the gene ATR and acute myeloblastic leukemia with maturation.